SCHEMBL20140187

SCHEMBL20140187

Cc1cc(Cc2ccc3c(c2)CC3)cc(Br)c1OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRB P10828 5/20 0.42
THRA P10827 4/20 0.42
HRH3 Q9Y5N1 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 4/20 0.38
GAA P10253 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
DHODH Q02127 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
BLM P54132 1/20 0.38
HPGD P15428 1/20 0.38
TP53 P04637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CHRNA7 P36544 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20139443 0.81 RAB9A (0.48) HRH3SMN1; SMN2KDM4EHPGDCHRNA7
SCHEMBL20139491 0.77 HTR2A (0.45) HRH3SMN1; SMN2MAPTTDP1CHRNA7
SCHEMBL20139420 0.77 THRB (0.39) THRBTHRAHRH3SMN1; SMN2MAPT
SCHEMBL12440971 0.74 MEN1 (0.55) THRBTHRASMN1; SMN2MAPTGAA
SCHEMBL646805 0.72 ALDH1A1 (0.51) THRBTHRASMN1; SMN2MAPTGAA
SCHEMBL15026101 0.72 THRB (0.56) THRBTHRASMN1; SMN2MAPTGAA
SCHEMBL20141555 0.71 HTR2A (0.44) HRH3SMN1; SMN2MEN1KMT2ACHRNA7
SCHEMBL20139411 0.71 CHRNA7 (0.47) HRH3MEN1KMT2ACHRNA7
SCHEMBL25817250 0.71 THRB (0.54) THRBTHRASMN1; SMN2MAPTGAA
SCHEMBL20140091 0.70 SLC5A1 (0.42) HRH3SMN1; SMN2MEN1KMT2ACHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-10-27 US disclosed
WO-2018089449-A1 BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 THRB 2068/4885THRA 3542/4885HRH3 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.